

CITATION REPORT

List of articles citing

Potential role of drug transporters in the pathogenesis of medically intractable epilepsy

DOI: 10.1111/j.0013-9580.2005.31904.x
Epilepsia, 2005, 46, 224-35.

Source: <https://exaly.com/paper-pdf/38244205/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
246	The pharmacokinetics and interactions of new antiepileptic drugs: an overview. 2005 , 27, 722-6		33
245	Brain inflammation in epilepsy: experimental and clinical evidence. <i>Epilepsia</i> , 2005 , 46, 1724-43	6.4	791
244	Response to antiepileptic drug therapy: winners and losers. <i>Epilepsia</i> , 2005 , 46 Suppl 10, 31-2	6.4	7
243	Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. <i>Epilepsia</i> , 2005 , 46, 858-77	6.4	347
242	Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. <i>Epilepsia</i> , 2005 , 46, 967-9	6.4	110
241	Diagnosing and predicting refractory epilepsy. 2005 , 181, 36-9		68
240	Genetics of drug resistance in epilepsy. 2005 , 5, 307-11		5
239	Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. 2005 , 6, 411-7		99
238	The role of common variation in drug transporter genes in refractory epilepsy. 2005 , 6, 1305-12		14
237	Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. 2005 , 314, 725-31		76
236	The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. 2005 , 7, 18-36		67
235	RLIP76, a non-ABC transporter, and drug resistance in epilepsy. 2005 , 6, 61		64
234	Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. 2005 , 7, E532-43		78
233	Combination therapy in epilepsy: when and what to use. 2006 , 66, 1817-29		116
232	Refractory epilepsy: mechanisms and solutions. 2006 , 6, 397-406		127
231	P-glycoprotein recognition of substrates and circumvention through rational drug design. 2006 , 3, 3-25		180
230	Modern antiepileptic drugs: guidelines and beyond. 2006 , 19, 175-80		17

229	The blood-brain barrier: Its implications in neurological disease and treatment. 2006 , 2, 18-25		3
228	Diagnosing refractory epilepsy: response to sequential treatment schedules. 2006 , 13, 277-82		250
227	Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. <i>Epilepsia</i> , 2006 , 47, 449; author reply 450	6.4	6
226	Response: Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. <i>Epilepsia</i> , 2006 , 47, 450-450	6.4	
225	Central and peripheral benzodiazepine receptors. <i>Epilepsia</i> , 2006 , 47, 450-1	6.4	1
224	Epileptogenesis due to peripheral injury as a cause of focal epilepsy. <i>Epilepsia</i> , 2006 , 47, 451; author reply 451-2	6.4	1
223	Response: Epileptogenesis due to Peripheral Injury as a Cause of Focal Epilepsy. <i>Epilepsia</i> , 2006 , 47, 451-452	6.4	3
222	Insulinoma presenting as refractory late-onset epilepsy. <i>Epilepsia</i> , 2006 , 47, 452; author reply 452	6.4	4
221	Response: Insulinoma Presenting as Refractory Late-onset Epilepsy. <i>Epilepsia</i> , 2006 , 47, 452-452	6.4	
220	Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. <i>Epilepsia</i> , 2006 , 47, 681-94	6.4	135
219	Epileptogenesis and rational therapeutic strategies. 2006 , 113, 139-55		39
218	Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. 2006 , 32, 51-63		60
217	Targeting multidrug resistance in cancer. 2006 , 5, 219-34		2649
216	Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. <i>Epilepsy Research</i> , 2006 , 68, 213-28	3.7	111
215	Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study. 2006 , 27, 245-51		22
214	In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. <i>Brain Research</i> , 2006 , 1086, 201-13	3.7	20
213	Update on pharmacogenetics in epilepsy: a brief review. 2006 , 5, 189-96		59
212	Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. 2006 , 129, 3290-306		56

211	ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. 2006 , 7, 551-61	137
210	Molecular and cellular mechanisms of pharmacoresistance in epilepsy. 2006 , 129, 18-35	287
209	Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. 2006 , 7, 89-103	14
208	Antiepileptic medication during pregnancy: does fetal genotype affect outcome?. 2007 , 62, 120-7	37
207	Etiology and management of refractory epilepsies. 2007 , 3, 320-30	22
206	Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. 2007 , 81, 299-311	10
205	The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. 2007 , 71, 884-92	32
204	Association of polymorphisms in NR112 and ABCB1 genes with epilepsy treatment responses. 2007 , 8, 1151-8	51
203	Clinical implications of mechanisms of resistance to antiepileptic drugs. 2007 , 13, S38-46	8
202	Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. 2007 , 16, 493-503	45
201	Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. 2007 , 11, 112-7	79
200	[18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. 2007 , 52, 695-707	70
199	TDAG51 in the anterior temporal neocortex of patients with intractable epilepsy. 2007 , 425, 53-8	7
198	Multidrug resistance in epilepsy: a pharmacogenomic update. 2007 , 8, 1441-9	38
197	Various pharmacogenetic aspects of antiepileptic drug therapy: a review. 2007 , 21, 143-64	29
196	Medical treatment in children with central nervous system malformations. 2008 , 87, 555-68	
195	Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. 2007 , 68, 1106-10	25
194	Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection?. 2007 , 258, 84-92	41

193	Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics. 2007 , 85, 3160-70		41
192	Formulation of spray-dried phenytoin loaded poly(epsilon-caprolactone) microcarrier intended for brain delivery to treat epilepsy. 2007 , 96, 1018-30		21
191	Enaminones: Exploring additional therapeutic activities. 2007 , 96, 2509-31		70
190	HSPBAP1 is found extensively in the anterior temporal neocortex of patients with intractable epilepsy. 2007 , 61, 741-7		14
189	ABCB1 pharmacogenetics: progress, pitfalls, and promise. 2007 , 81, 265-9		114
188	Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. <i>Epilepsia</i> , 2007 , 48, 674-83	6.4	24
187	Drug resistance in epilepsy: more twists in the tale. <i>Epilepsia</i> , 2007 , 48, 2369-70	6.4	18
186	Drug resistance in epilepsy: why is a simple explanation not enough?. <i>Epilepsia</i> , 2007 , 48, 2370-2	6.4	31
185	Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy?. <i>Epilepsia</i> , 2007 , 48, 2372-4	6.4	20
184	Assessment of hairline EEG as a screening tool for nonconvulsive status epilepticus. <i>Epilepsia</i> , 2007 , 48, 2374-5; author reply 2375	6.4	3
183	Assessment of hairline EEG as a screening tool for nonconvulsive status epilepticus: Response to Bubrick et al.. <i>Epilepsia</i> , 2007 , 48, 2375-2375	6.4	
182	Next Month in <i>Epilepsia</i> . <i>Epilepsia</i> , 2007 , 48, 2376-2376	6.4	
181	Online Early. <i>Epilepsia</i> , 2007 , 48, 2376-2376	6.4	
180	Announcements. <i>Epilepsia</i> , 2007 , 48, 2376-2377	6.4	
179	Calendar of Meetings. <i>Epilepsia</i> , 2007 , 48, 2378-2378	6.4	
178	Means, motive, and opportunity: establishing culpability in pharmaco-resistant epilepsy. 2007 , 7, 51-3		4
177	A possible explanation for the paradox of hyperexcitability and epilepsy in "loss of function" voltage-gated sodium channel mutations. 2007 , 7, 54-55		0
176	Brain water and ion fluxes: a hard-to-die hypothesis to explain seizures. 2007 , 7, 56-7		1

175	The ketogenic diet: stoking the powerhouse of the cell. 2007 , 7, 58-60		6
174	P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro. <i>Epilepsy Research</i> , 2008 , 78, 40-9	3	25
173	Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. 2008 , 155, 1127-38		18
172	The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). 2008 , 13, 379-93		401
171	Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. 2008 , 42, 89-97		65
170	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. <i>Xenobiotica</i> , 2008 , 38, 802-32	2	424
169	[Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects]. 2008 , 54, 259-64		5
168	Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. 2008 , 54, 1006-16		61
167	Several major antiepileptic drugs are substrates for human P-glycoprotein. 2008 , 55, 1364-75		239
166	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. 2008 , 32, 1439-44		53
165	One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. 2008 , 30, 920-5		24
164	P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model. 2008 , 36, 1073-9		37
163	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. 2008 , 18, 390-402		44
162	Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. 2008 , 30, 173-80		51
161	Farmacogenética e antiepiléticos (farmacologia das drogas antiepiléticas: da teoria à prática). 2008 , 14, 51-56		4
160	PHARMACORESISTANCE Cellular and Molecular Mechanisms Contributing to Pharmacoresistance in Human Neocortical Tissue. 2009 , 1133-1138		0
159	PHARMACORESISTANCE Multidrug Resistance. 2009 , 1621-1626		
158	Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations. 2009 , 5, 1267-77		12

157	Suppression of the multidrug transporter P-glycoprotein using RNA interference in cultured rat astrocytes induced by coriaria lactone. 2009 , 31, 1084-91		8
156	MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. 2009 , 10, 711-3		19
155	The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. 2009 , 26, 2464-70		39
154	Gene expression analysis on anterior temporal neocortex of patients with intractable epilepsy. 2009 , 63, 1017-28		39
153	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23	6.4	184
152	Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. <i>Epilepsia</i> , 2009 , 50, 887-97	6.4	32
151	Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. <i>Epilepsia</i> , 2009 , 50, 1689-96	6.4	38
150	Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. 2009 , 10, 723-32		37
149	Reevaluating the mechanisms of focal ictogenesis: The role of low-voltage fast activity. <i>Epilepsia</i> , 2009 , 50, 2514-25	6.4	99
148	P-gp transporter and its role in neurodegenerative diseases. 2009 , 9, 209-17		23
147	Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. 2010 , 39, 192-7		31
146	Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. 2010 , 628, 57-66		31
145	Radiosynthesis and in vivo evaluation of [(11)C]MC80 for P-glycoprotein imaging. 2010 , 18, 6489-95		6
144	Transient improvement after brief antiepileptic drug withdrawal in the epilepsy monitoring unit—possible relationship to AED tolerance. <i>Epilepsia</i> , 2010 , 51, 811-7	6.4	4
143	Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. 2010 , 159, 1511-22		28
142	Genetic variations and response to antiepileptic drug. 2010 , 3, 65-71		
141	Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy. 2010 , 25, 1485-90		24
140	Frequency flow dynamics of epileptic brain. 2010 , 120, 222-5		2

139	Drug transporters are altered in brain, liver and kidney of rats with chronic epilepsy induced by lithium-pilocarpine. 2010 , 32, 106-12	10
138	Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. 2010 , 10, 1785-91	30
137	[Pharmacoresistant epilepsy - epidemiology and current studies]. 2010 , 44, 285-90	13
136	Pharmacogenetics and Pharmacogenomics. 2010 , 325-345	
135	In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. 2010 , 86, 899-905	40
134	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. 2010 , 58, 1019-32	85
133	In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter. 2010 , 37, 469-77	6
132	Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. 2010 , 19, 93-101	66
131	Antiepileptic drug therapy the story so far. 2010 , 19, 650-5	204
130	Verapamil attenuates the malignant treatment course in recurrent status epilepticus. 2010 , 17, 565-8	27
129	Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. 2010 , 53, 1883-97	94
128	Wavelet based algorithm for the estimation of frequency flow from electroencephalogram data during epileptic seizure. 2011 , 122, 680-6	10
127	Impaired mitochondrial energy production: the basis of pharmacoresistance in epilepsy. 2011 , 77, 536-40	20
126	Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. 2011 , 20, 387-94	23
125	Local delivery strategies in epilepsy: a focus on adenosine. 2011 , 20, 376-82	18
124	Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy. 2011 , 20, 546-53	11
123	Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic Border Collies. 2011 , 25, 484-9	15
122	Blood-Brain Barrier Permeability: From Bench to Bedside. 2011 ,	

121	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. <i>Epilepsia</i> , 2011 , 52, 1894-904	6.4	68
120	Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. <i>Brain Research</i> , 2011 , 1391, 114-24	3.7	29
119	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. 2011 , 12, 319-25		32
118	Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethyloperamide. <i>Epilepsy Research</i> , 2011 , 94, 18-25	3	44
117	Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. 2011 , 17, 2808-28		114
116	Overexpression of human MRP1 in neurons causes resistance to antiepileptic drugs in <i>Drosophila</i> seizure mutants. 2011 , 25, 201-6		9
115	Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. 2011 , 2011, 670613		30
114	An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood-brain barrier. 2011 , 13, 1087-97		10
113	Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. 2012 , 34, 518-25		32
112	Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. 2012 , 135, 1002-16		123
111	MK-801 prevents overexpression of multidrug resistance protein 2 after status epilepticus. 2012 , 34, 430-8		4
110	Synthesis of benzothiazole derivatives having acetamido and carbothioamido pharmacophore as anticonvulsant agents. 2012 , 21, 2661-2670		21
109	Genetics of temporal lobe epilepsy. 2012 , 34, 609-16		14
108	Role of ABC transporters in the pathogenesis of Alzheimer's disease. 2012 , 3, 820-31		94
107	The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. 2012 , 64, 1011-9		70
106	Deep brain stimulation for refractory epilepsy. 2012 , 8, 805-16		18
105	Cerebral expression of drug transporters in epilepsy. 2012 , 64, 919-29		66
104	The transport of antiepileptic drugs by P-glycoprotein. 2012 , 64, 930-42		155

103	Pharmacoresistance in Epilepsy. 2013 ,		
102	Potential role for human P-glycoprotein in the transport of lacosamide. <i>Epilepsia</i> , 2013 , 54, 1154-60	6.4	39
101	Design and synthesis of some new quinazolin-4-(3H)-ones as anticonvulsant and antidepressant agents. 2013 , 36, 61-8		20
100	The methylation hypothesis of pharmacoresistance in epilepsy. <i>Epilepsia</i> , 2013 , 54 Suppl 2, 41-7	6.4	68
99	Advancing the management of childhood epilepsies. 2013 , 17, 334-47		14
98	CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. 2013 , 2013, 526837		24
97	PET Imaging of the Serotonergic 5-HT1A System. 2013 ,		
96	Polymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results. 2014 , 20, 1654-61		12
95	Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. <i>Frontiers in Neurology</i> , 2014 , 5, 11	4.1	65
94	Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis. 2014 , 121, 717-24		9
93	Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. 2014 , 23, 36-40		40
92	Role of blood-brain barrier in temporal lobe epilepsy and pharmacoresistance. 2014 , 277, 455-73		61
91	A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures. <i>Epilepsy Research</i> , 2014 , 108, 1642-51	3	22
90	In vitro transport assays of rufinamide, pregabalin, and zonisamide by human P-glycoprotein. <i>Epilepsy Research</i> , 2014 , 108, 359-66	3	31
89	Mechanisms of Drug Resistance and Tolerance. 2015 , 92-102		1
88	Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. 2015 , 40, 315-9		17
87	Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions. 2015 , 5, 1-8		33
86	The clinical pharmacology profile of the new antiepileptic drug perampamil: A novel noncompetitive AMPA receptor antagonist. <i>Epilepsia</i> , 2015 , 56, 12-27	6.4	146

85	The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). 2015 , 93, 7-14		56
84	Change of MicroRNA-134, CREB and p-CREB expression in epileptic rat. 2015 , 8, 292-8		6
83	ABCB1 G2677T/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians. <i>Epilepsy Research</i> , 2015 , 115, 100-8	3	13
82	The recessive model of MRP2 G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: a systematic review and meta-analysis. <i>Epilepsy Research</i> , 2015 , 112, 56-63	3	14
81	Brain Tumor-Related Epilepsy: Introduction and Overview. 2015 , 1-9		1
80	[Predictors factors of refractory epilepsy in childhood]. 2015 , 171, 730-5		4
79	Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. 2015 , 14, 233-272		31
78	Preclinical Drug Development. 2016 ,		
77	The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. 2016 , 9, 47-58		24
76	Managing drug-resistant epilepsy: challenges and solutions. 2016 , 12, 2605-2616		89
75	Organic anion transporting polypeptide 2 transports valproic acid in rat brain microvascular endothelial cells. 2016 , 38, 634-9		12
74	The role of blood-brain barrier in the development of childhood febrile seizures and temporal lobe epilepsy. 2016 , 42, 579-584		
73	Discovering New Antiepileptic Drugs Addressing the Transporter Hypothesis of Refractory Epilepsy: Ligand-Based Approximations. 2016 , 259-279		0
72	Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy. 2016 , 56 Suppl 7, S173-92		14
71	Low dose verapamil as an adjunct therapy for medically refractory epilepsy - An open label pilot study. <i>Epilepsy Research</i> , 2016 , 126, 197-200	3	17
70	Association between genetic polymorphism and the effect on epilepsy following phenytoin treatment. 2016 , 12, 1780-1784		7
69	Computational approaches for innovative antiepileptic drug discovery. 2016 , 11, 1001-16		8
68	Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice. 2016 , 109, 183-195		36

67	The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy. 2016 , 16, 9-15		20
66	A multimodal Pepstatin A peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats. <i>Biomaterials</i> , 2016 , 76, 173-86	15.6	14
65	Clinical efficacy of deep brain stimulation for the treatment of medically refractory epilepsy. 2016 , 140, 11-25		49
64	Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. 2017 , 37, 97-105		6
63	Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy. 2017 , 61, 553-562		9
62	Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis. <i>BMC Neurology</i> , 2017 , 17, 32	3.1	50
61	P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy. 2017 , 14, 999-1011		44
60	Status epilepticus in dogs and cats, part 1: etiopathogenesis, epidemiology, and diagnosis. 2017 , 27, 278-287		13
59	Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition. 2017 , 12, 593-601		58
58	Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy. 2017 , 19, 973-988		34
57	Role of P-glycoprotein inhibitors in children with drug-resistant epilepsy. 2017 , 136, 639-644		9
56	Outside the box: Medications worth considering when traditional antiepileptic drugs have failed. 2017 , 50, 173-185		9
55	The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. 2017 , 37, 6-14		24
54	Pharmacogenomics in Clinical Care and Drug Discovery. 2017 , 281-303		
53	Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. <i>Frontiers in Neurology</i> , 2017 , 8, 301	4.1	184
52	Genotypes and haplotypes of ABCB1 contribute to TAC chemotherapy response in Malaysian triple negative breast cancer patients. 2018 , 16, 21-27		0
51	Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population. 2018 , 128, 705-714		13
50	Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. 2018 , 14, 505-512		13

49	In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. <i>Epilepsy Research</i> , 2018 , 146, 63-86	3	21
48	Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy. <i>International Journal of Pharmaceutics</i> , 2018 , 547, 10-23	6.5	18
47	Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients. 2019 , 12, 87-95		11
46	ABCB1 c.-6-180T>G polymorphism and clinical risk factors in a multi-breed cohort of dogs with refractory idiopathic epilepsy. <i>Veterinary Journal</i> , 2019 , 253, 105378	2.5	2
45	Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. <i>Journal of Neuroinflammation</i> , 2019 , 16, 197	10.1	42
44	Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy. <i>Molecular Brain</i> , 2019 , 12, 92	4.5	4
43	Dravet Syndrome: Early Diagnosis and Emerging Therapies. <i>Journal of Pediatric Epilepsy</i> , 2019 , 08, 031-037		1
42	An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy. <i>Pharmacology & Therapeutics</i> , 2019 , 201, 77-93	13.9	51
41	MicroRNA-146a-5p Downregulates the Expression of P-Glycoprotein in Rats with Lithium-Pilocarpine-Induced Status Epilepticus. <i>Biological and Pharmaceutical Bulletin</i> , 2019 , 42, 744-750	2.3	10
40	ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. <i>Pharmacological Research</i> , 2019 , 144, 357-376	10.2	25
39	Imaging Mechanisms of Drug Resistance in Experimental Models of Epilepsy. 2019 , 148-156		0
38	Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population. <i>Disease Markers</i> , 2019 , 2019, 1343650	6.5	12
37	The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A. <i>Xenobiotica</i> , 2020 , 50, 354-362	2	5
36	Activation of adenosine receptors modulates the efflux transporters in brain capillaries and restores the anticonvulsant effect of carbamazepine in carbamazepine resistant rats developed by window-pentylene tetrazole kindling. <i>Brain Research</i> , 2020 , 1726, 146516	3.7	2
35	Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 19, 157-167	10.7	13
34	Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children. <i>Epilepsy Research</i> , 2020 , 168, 106485	3	2
33	Association of ABCB1 gene polymorphism (C1236T and C3435T) with refractory epilepsy in Iraqi patients. <i>Molecular Biology Reports</i> , 2020 , 47, 4245-4254	2.8	3
32	Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity. <i>International Journal of Pharmaceutics</i> , 2020 , 577, 119033	6.5	30

31	Advances in nanomedicines for diagnosis of central nervous system disorders. <i>Biomaterials</i> , 2021 , 269, 120492	15.6	14
30	The ADME Encyclopedia. 2021 , 1-9		
29	Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy. <i>Cureus</i> , 2021 , 13, e15012	1.2	
28	The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
27	The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. <i>Frontiers in Neurology</i> , 2021 , 12, 674483	4.1	11
26	Molecular Chaperones and miRNAs in Epilepsy: Pathogenic Implications and Therapeutic Prospects. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	
25	Multi-omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy. <i>Epilepsia Open</i> , 2021 ,	4	2
24	Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients. <i>BMC Neurology</i> , 2021 , 21, 367	3.1	2
23	The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug-resistant epilepsy. <i>Epilepsia Open</i> , 2021 ,	4	0
22	Drug Interactions. 344-359		2
21	On the Development of New Antiepileptic Drugs for the Treatment of Pharmacoresistant Epilepsy: Different Approaches to Different Hypothesis. 2013 , 207-224		6
20	Prenatal Development of the Human Blood-Brain Barrier. 2009 , 53-75		4
19	Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance. <i>PLoS ONE</i> , 2014 , 9, e89253	3.7	14
18	Chemotherapy-Induced Cognitive Decline: Moving from the Mechanistic Debate towards Prevention and Treatment – A Clinical Review. <i>Journal of Cancer Therapy</i> , 2019 , 10, 985-1012	0.2	4
17	Why Is There a Similar Ceiling Effect for the Efficacy of Most If Not All Antiepileptic Drugs in Adult Epilepsy? Reaching the Ceiling or Hitting the Wall?. 2008 , 433-446		
16	Drug Transporters in Health and Disease. <i>Methods and Principles in Medicinal Chemistry</i> , 2009 , 387-415	0.4	
15	Role of Biotechnology in Drug Delivery to the Nervous System. 2013 , 477-511		
14	Genes Involved in Pharmacoresistant Epilepsy. 2013 , 11-25		1

13	[Epigenetic modifications of chromatin in epilepsy: a potential mechanism of pharmacoresistance?]. <i>Zhurnal Nevrologii I Psikhatrii Imeni S S Korsakova</i> , 2017 , 117, 17-21	0.4	
12	Modulation of emotion perception and memory via sub-threshold amygdala stimulation in humans.		
11	P-Glycoprotein Efflux Transporters and Its Resistance Its Inhibitors and Therapeutic Aspects.		1
10	Echinoderm microtubule-associated protein -like protein 5 in anterior temporal neocortex of patients with intractable epilepsy. <i>Iranian Journal of Basic Medical Sciences</i> , 2015 , 18, 1008-13	1.8	6
9	The Electrophysiological Properties of Cortical Neurons in the Epileptic Foci of Children with Refractory Temporal Lobe Epilepsy. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2022 , 58, 215-229 ⁵		
8	A Complex Systems View on the Current Hypotheses of Epilepsy Pharmacoresistance.. <i>Epilepsia Open</i> , 2022 ,	4	
7	Cadherins and the pathogenesis of epilepsy.. <i>Cell Biochemistry and Function</i> , 2022 ,	4.2	0
6	Drug Distribution. 2022 , 349-356		
5	Implication of ABC transporters in non-proliferative diseases. 2022 , 935, 175327		1
4	Levosulpiride-loaded nanostructured lipid carriers for brain delivery with antipsychotic and antidepressant effects. 2022 , 121198		2
3	Valproic acid-induced upregulation of multidrug efflux transporter ABCG2/BCRP via PPAR α -dependent mechanism in human brain endothelial cells. MOLPHARM-AR-2022-000568		0
2	Translational Considerations in the Development of Intranasal Treatments for Epilepsy. 2023 , 15, 233		0
1	Personalized antiseizure medication therapy in critically ill adult patients.		0